IP Library › Granted Patent US 12,258,387
Granted Patent B2
US 12,258,387 · App. 17/703,747 · Granted Mar 25, 2025

Anti-BAG3 antibodies as therapeutic reagent in cardiovascular disease

Inventors: Maria Caterina Turco (Avellino, IT); Liberato Marzullo (Scalea, IT); Alessandra Rosati (Baronissi, IT); Margot De Marco (Salerno, IT); Anna Basile (Bracigliano, IT)
Assignee: FIBROSYS S.R.L.
C07K16/18A61K39/3955A61P9/04A61P9/10A61K2039/505C07K2317/20C07K2317/24C07K2317/54C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/626
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,387
App. No.
17/703,747
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention relates to the use of anti-BAG3 antibodies and its pharmaceutical formulation in the treatment of cardiovascular diseases.

Claims (13)

1. A method for treating a cardiovascular disease in a patient, comprising the step of administering a pharmaceutical composition consisting essentially of an anti-BAG3 antibody to a patient in need thereof, where the cardiovascular disease is selected from the group consisting of: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure, and iatrogenic heart disease,

wherein the anti-BAG3 antibody is:

(i) a humanized antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 12, 14, 16, or 18, and a light chain comprising the amino acid sequence of SEQ ID NO: 20, 22, 24, or 26; or

(ii) a humanized antibody comprising a heavy chain comprising H-CDR1 having the amino acid sequence of SEQ ID NO: 5, H-CDR2 having the amino acid sequence of SEQ ID NO: 6, and H-CDR3 having the amino acid sequence of SEQ ID NO: 7, and a light chain comprising L-CDR1 having the amino acid sequence of SEQ ID NO: 8, L-CDR2 having the amino acid sequence of SEQ ID NO: 9, and L-CDR3 having the amino acid sequence of SEQ ID NO: 10.

2. The method according to claim 1 , wherein the anti-BAG3 antibody is a humanized antibody comprising the heavy chain comprising H-CDR1 having the amino acid sequence of SEQ ID NO: 5, H-CDR2 having the amino acid sequence of SEQ ID NO: 6, and H-CDR3 having the amino acid sequence of SEQ ID NO: 7, and the light chain comprising L-CDR1 having the amino acid sequence of SEQ ID NO: 8, L-CDR2 having the amino acid sequence of SEQ ID NO: 9, and L-CDR3 having the amino acid sequence of SEQ ID NO: 10.

3. The method according to claim 2 , wherein the anti-BAG3 antibody is a humanized antibody comprising:

a) a heavy chain amino acid sequence comprising SEQ ID NO: 12 or an amino acid sequence having a sequence identity of at least 95% thereof, and

b) a light chain amino acid sequence comprising SEQ ID NO: 20 or an amino acid sequence having a sequence identity of at least 95% thereof.

4. The method according to claim 2 , wherein the heavy chain of the humanized anti-BAG3 antibody comprises the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18.

5. The method according to claim 2 , wherein the light chain of the humanized anti-BAG3 antibody comprises the amino acid sequence of SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26.

6. The method according to claim 1 , wherein the pharmaceutical composition is administered by oral administration, parenteral administration, or topical administration.

7. The method according to claim 6 , wherein the pharmaceutical composition is orally administered in a form of tablets, capsules, solutions, suspensions, granules, or oily capsules.

8. The method according to claim 6 , wherein the parenteral administration is intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: BIOUNIVERSA S.R.L.
To: FIBROSYS S.R.L.
Reel/Frame 059604/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: TURCO, MARIA CATERINA; MARZULLO, LIBERATO; ROSATI, ALESSANDRA; DE MARCO, MARGOT; BASILE, ANNA
To: BIOUNIVERSA S.R.L.
Reel/Frame 059812/0809 →
Priority Claims (2)
IT 102017000087307 · Jul 28, 2017 · national
IT 102017000113648 · Oct 10, 2017 · national
Continuity (2)
Division 17040468
Related Publication 20220213182A1 · Jul 7, 2022
References Cited (32)
US 10889644B2 · Turco et al. · 2021 [cited by applicant]
US 20160168255A1 · Turco · 2016 [cited by examiner]
EP 0239400A2 · 1987 [cited by applicant]
EP 0451216B2 · 2012 [cited by applicant]
WO WO03055908A2 · 2003 [cited by examiner]
WO 2011067377A1 · 2011 [cited by applicant]
WO 2015117010A2 · 2015 [cited by applicant]
WO 2017031182A2 · 2017 [cited by applicant]
WO 2017076878A1 · 2017 [cited by applicant]
Benjamini et al., 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Ferrara et al (2015. mAbs. 7(1): 32-41. [cited by examiner]
International Search Report of PCT/EP2018/070259, mailed Jul. 9, 2018, 5 pages., Jul. 9, 2018. [cited by applicant]
Ammirante, Massimo , et al., “IKKy protein is a target of BAG3 regulatory activity in human tumor growth”, www.pnas.org/cgi/doi/10.1073/pnas.0907696107., 2010, pp. 1-6. [cited by applicant]
Behl, Christian , “Breaking BAG: The Co-Chaperone BAG3 in Health and Disease”, Trends in Pharmacological Sciences, Aug. 2016, vol. 37, No. 8, 2016, pp. 672-688. [cited by applicant]
Belkaya, Serkan , et al., “Autosomal Recessive Cardiomyopathy Presenting as Acute Myocarditis”, Journal of the American College of Cardiology , vol. 69, No. 13, 2017, 2017, pp. 1653-1665. [cited by applicant]
Carriizzo, Albino , et al., “The prosurvival protein BAG3: a new participant in vascular homeostasis”, Cell Death and Disease (2016) 7, e2431; doi: 10.1038/cddis.2016.321, Official journal of the Cell Death Differentiat… [cited by applicant]
Ceran, Ceyhan , et al., “Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-a”, BioMed Central 2012, 2012, pp. 1-16. [cited by applicant]
De Marco, Margot , et al., “BAG3 Protein in Advanced-Stage Heart Failure”, JACC: Heart Failure vol. 2, No. 6, 2014, pp. 673-675. [cited by applicant]
De Marco, M. , et al., “Detection of soluble BAG3 and anti-BAG3 antibodies in patients with chronic heart failure”, Cell Death and Disease (2013) 4, e495; doi:10.1038/cddis.2013.8 & 2013 Macmillan Publishers Limited All… [cited by applicant]
Festa, Michelina , et al., “BAG3 Protein Is Overexpressed in Human Glioblastoma and is a Potential Target for Therapy”, The American Journal of Pathology, vol. 178, No. 6, Jun. 2011, 2011, pp. 2504-2512. [cited by applicant]
Gourdie, Robert G., et al., “Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease”, Nature Reviews | Drug Discovery; vol. 15, Sep. 2016, 2016, pp. 620-638. [cited by applicant]
Keah, Hooi Hong , et al., “Direct synthesis and characterisation of multi-dendritic peptides for use as immunogens”, Center for Biopress Technology, Dept. of Biochemistry and Molecular Biology; Journal of Peptide Resear… [cited by applicant]
Kettleborough, Catherine A., et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the Importance of framework residues on loop confirmation”, Protein Engineering, vol. 4, No. 7, 1991, pp. 773-783. [cited by applicant]
Ota, Seisuke , et al., “Cellular Processing of a Multibranched Lysine Core with Tumor Antigen Peptides and Presentation of Peptide Epitopes Recognized by Cytotoxic T Lymphocytes on Antigen-presenting Cells”, Cancer Rese… [cited by applicant]
Polizzotti, Brian D., et al., “A cryoinjury model in neonatal mice for cardiac translational and regeneration research”, Author manuscript, Mar. 2016, 2016, pp. 542-552. [cited by applicant]
Rosati, Alessandra , et al., “BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages”, Nature Communication; DOI: 10.1038/ncomms9695, 2015, pp. 1-11. [cited by applicant]
Rosati, A. , et al., “BAG3: a multifaceted protein that regulates major cell pathways”, Citation: Cell Death and Disease (2011) 2, eK; doi:10.1038/cddis.2011.24, 2011, pp. 1-6. [cited by applicant]
Rosati, Alessandra , et al., “Expression of the Antiapoptotic Protein BAG3 is a Feature of Pancreatic Adenocarcinoma and Its Overexpression is Associated With Poorer Survival”, Short Communications, The American Journal… [cited by applicant]
Ruparelia, Neil , et al., “Inflammatory processes in cardiovascular disease: a route to targeted therapies”, Nature Reviews | Cardiology, doi: 10.1038/nrcardio.2016.185, Dec. 2016, 2016, pp. 1-12. [cited by applicant]
Tam, James P., “Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide sytsem”, Proc. Natl. Acad. Sci. USA, vol. 85, Aug. 1988, 1988, pp. 5409-5413. [cited by applicant]
Tassone, P. , et al., “CD35 is rapidly and transiently upregulated on phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7)”, CD35 upregulation on PHA-Stimulated P… [cited by applicant]
Travers, Joshua G., et al., “Cardiac Fibrosis—The Fibroblast Awakens”, Heart Institute, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, OH., 2016, pp. 1021-1040. [cited by applicant]